Breaking News, Collaborations & Alliances

UI Pharmaceuticals Partners with MimiVax for Glioblastoma Vaccine

Will manufacture SurVaxM, a novel immunotherapeutic vaccine designed to treat glioblastoma, for use in clinical trials.

Author Image

By: Charlie Sternberg

Associate Editor

UI Pharmaceuticals (UIP), a strategic asset of the University of Iowa (UI) College of Pharmacy, has partnered with MimiVax to manufacture SurVaxM, a novel immunotherapeutic vaccine designed to treat glioblastoma, one of the most aggressive forms of brain cancer, for use in clinical trials. “This collaboration combines MimiVax’s innovative research with UIP’s expertise in formulation development and sterile production, accelerating the path to potentially transformative therapies for patients,...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters